Company news

ALX Oncology Holdings Inc. news in 2024

ALX Oncology Holdings Inc.'s news releases, calls and decks from 2024, newest first.

View company

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

December 17, 2024

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

December 9, 2024

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

November 13, 2024

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

October 31, 2024

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

September 8, 2024

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

September 3, 2024

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

August 5, 2024

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

July 30, 2024

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

June 1, 2024

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 28, 2024

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

ALX Oncology Appoints Allison Dillon as Chief Business Officer

May 6, 2024

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

April 29, 2024

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

April 23, 2024

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

April 8, 2024

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 6, 2024

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

March 4, 2024

ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024